Liao Tsai-Ling, Chen Der-Yuan, Hsieh Shie-Liang, Yang Ying-Ying, Chen Yi-Ming, Tang Kuo-Tung, Chang Chung-Hsin, Yang Sheng-Shun
Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001149.
Immune system activation, along with lipotoxicity due to excessive lipid droplet (LD) accumulation in the liver, are key drivers of NASH. Extracellular vesicles (EVs) released by cells that carry biological signals contribute to intercellular communication. However, the roles of immune cell-derived EVs in the pathogenesis of NASH are unclear.
Platelets are abundant in blood. We explored the role of platelet-derived EVs (pEVs) in LD accumulation from 30 patients with nonalcoholic fatty liver disease of different severity as well as 20 healthy subjects, a rat model, and an in vitro cell-based assay. There was increased platelet activation, accompanied by pEVs release, in NASH patients/rat model, and palmitate-treated cells. The mitochondria in the platelets and pEVs from NASH patients/rats were increased but dysfunctional, including a reduction in fatty acid β-oxidation, inactivated acetyl-CoA carboxylase 2, and suppressed oxidative phosphorylation system complex II/III/IV activity. These damaged mitochondria could be transferred to hepatocytes through pEVs to increase the number of lipid droplet-bound mitochondria. An increase in dysfunctional lipid droplet-bound mitochondria in hepatocytes affects lipid metabolism, resulting in excessive LD accumulation, elevated mitochondrial reactive oxygen species production, and apoptosis.
We offer a novel molecular mechanism that connects platelets, pEVs, and excessive LD accumulation to the development of NASH. Our results suggest that NASH progression may be alleviated by specifically inhibiting the production and release of pEVs, or by targeting pEV components and inhibiting their uptake. Additional experiments are required to confirm this potentiality.
免疫系统激活以及肝脏中因脂质滴(LD)过度积累导致的脂毒性是NASH的关键驱动因素。携带生物信号的细胞释放的细胞外囊泡(EVs)有助于细胞间通讯。然而,免疫细胞衍生的EVs在NASH发病机制中的作用尚不清楚。
血液中血小板丰富。我们从30例不同严重程度的非酒精性脂肪性肝病患者以及20名健康受试者、大鼠模型和体外细胞实验中探索了血小板衍生的EVs(pEVs)在LD积累中的作用。在NASH患者/大鼠模型以及棕榈酸处理的细胞中,血小板活化增加,同时伴有pEVs释放。NASH患者/大鼠的血小板和pEVs中的线粒体数量增加但功能失调,包括脂肪酸β-氧化减少、乙酰辅酶A羧化酶2失活以及氧化磷酸化系统复合物II/III/IV活性受到抑制。这些受损的线粒体可通过pEVs转移至肝细胞,从而增加与脂质滴结合的线粒体数量。肝细胞中功能失调的与脂质滴结合的线粒体数量增加会影响脂质代谢,导致LD过度积累、线粒体活性氧生成增加以及细胞凋亡。
我们提出了一种新的分子机制,将血小板、pEVs和LD过度积累与NASH的发展联系起来。我们的结果表明,通过特异性抑制pEVs的产生和释放,或靶向pEVs成分并抑制其摄取,可能会缓解NASH的进展。需要进一步的实验来证实这种可能性。